Loading clinical trials...
Loading clinical trials...
The purpose of this post-approval study is to demonstrate that iLux treatment offers comparable treatment effectiveness to LipiFlow for MGD treatment at 12 months post single treatment.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Alcon Research
NCT03767530 · Meibomian Gland Dysfunction
NCT06220474 · Dry Eye Syndromes, Meibomian Gland Dysfunction
NCT07453212 · Dry Eye, Evaporative Dry Eye Disease, and more
NCT06542276 · MGD-Meibomian Gland Dysfunction
NCT07365735 · Meibomian Gland Dysfunction (Disorder)
Alcon Investigator 9083
Long Beach, California
Alcon Investigator 9081
Los Angeles, California
Alcon Investigator 9084
San Diego, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions